Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Sales and marketing

General and administrative

Restructuring

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Doximity

Doximity, Inc. develops an online healthcare resource and interactive platform. The Company cloud-based platform enables its members to collaborate with their colleagues, securely coordinate patient care, and conducts virtual patient visits. Doximity serves customers in the United States.

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

Doximity surpasses Q4 revenue expectations and eyes continued growth

Doximity's Q4 2023 performance exceeded expectations, showcasing strong financial metrics and strategic investments. The company's outlook for Q1 2024 indicates continued growth, with a focus on topline expansion and product innovation. While facing challenges in pricing strategies and competitive landscape, Doximity is well-positioned to capitalize on opportunities in the healthcare technology sector.

Doximity reports strong Q1 results but lowers 2024 guidance

Doximity delivered strong financial performance in Q1, but challenges in upsell close rates led to a downward revision in annual guidance. The company's focus on innovation, expansion, and shareholder value, along with a cautious outlook for the remainder of the year, presents a mixed picture of opportunities and challenges for investors.

Doximity reports strong Q3 earnings, eyes growth amid product challenges

Doximity's Q3 performance demonstrated resilience and growth potential despite challenges in meeting annual guidance due to product delays.
The company's focus on innovation, strong client relationships, and strategic investments position it well for future growth and market leadership.
With a commitment to R&D, expanding product offerings, and maintaining pricing discipline, Doximity aims to capitalize on opportunities and navigate challenges for sustained success.

Doximity surpasses Q4 revenue targets, poised for growth and innovation

Doximity's Q4 performance exceeded expectations, with robust revenue growth, strong margins, and strategic investments in new products and talent.
While facing challenges like flat growth in certain segments and pricing adjustments, the company is well-positioned to capitalize on opportunities in network expansion and technology innovation.
With a focus on enhancing user experience, driving engagement, and optimizing revenue streams, Doximity is poised for continued success and value creation for shareholders.
The company's financial health, innovative product offerings, and market positioning indicate a promising outlook for sustained growth and competitive advantage in the healthcare technology sector.

Doximity surpasses Q1 revenue expectations, faces upsell challenges

Doximity's Q1 performance was strong, but challenges in upsells prompted a staff reduction and revised guidance. The company is optimistic about long-term growth, leveraging new products and a self-serve ad platform for future success.

Doximity beats Q2 expectations, eyes growth amidst market uncertainties

Doximity's strong Q2 performance exceeded revenue and EBITDA guidance, driven by record physician engagement and new product success.
While facing market uncertainties and competition challenges, the company sees opportunities in pricing strategies and continued growth.
Investments in high-touch services, Telehealth, and video products are paying off, with a focus on enhancing client offerings.
Integration with IQVIA for real-time ROI analysis positions Doximity for future growth and client value creation.

Doximity beats Q3 revenue, eyes growth through AI products

Doximity's Q3 performance exceeded expectations with strong revenue and margin growth. The company faces challenges with elongated sales cycles but has opportunities for growth through AI products and new modules. Overall, Doximity's competitive position remains strong in the market.

Doximity exceeds Q4 revenue, eyes mid-teens growth post-COVID

Doximity's Q4 earnings call highlighted strong financial performance, customer satisfaction initiatives, and growth opportunities in digital marketing and new business segments. While facing challenges in growth slowdowns and market uncertainties, the company is leveraging strengths in optimized margins, visibility into revenue guidance, and customer commitment to drive future success.

Doximity excels in Q1 2025, driving growth through client value

Doximity's Q1 2025 performance reflects strong revenue growth, operational efficiency, and client value proposition.
The company's focus on innovation, customer engagement, and strategic insights positions it well for sustained growth.
Despite challenges, Doximity's proactive approach to industry dynamics and growth opportunities bodes well for future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Doximity, Inc. engages in the development and operation of an online platform for medical professionals. Its cloud-based software has the ability to enable users to collaborate with their colleagues, coordinate patient care, conduct virtual patient visits, stay up to date with the latest medical news and research, and manage their careers. The company was founded by Shari Buck, Konstantin Guericke, Nate Gross, and Jeffrey A. Tangney on April 16, 2010 and is headquartered in San Francisco, CA.

Q4 total revenues of $93.7 million , up 40% year-over-year Q4 net income margin of 39% and adjusted EBITDA margin of 42% Fiscal Year 2022 total revenues of $343.5 million, up 66% year-over-year Fiscal year 2022 net income margin of 45% and adjusted EBITDA margin of 44% SAN FRANCISCO, May 17, 2022 /PRNewswire/ -- Doximity, Inc. (NYSE: DOCS), the leading digital platform for U.S. medical professionals, today announced results for the fiscal 2022 fourth quarter and fiscal year ended March 31, 2022. "We're proud to now serve over 2 million US healthcare professionals, including over 80% of US physicians and over 50% of Physician Assistants and Nurse Practitioners," said Jeff Tangney, co-founder & CEO at Doximity.

Doximity Announces Fourth Quarter and Fiscal Year 2022 Financial Results

Doximity Inc. is scheduled to report earnings after Tuesday's close. Here's a closer look.

Earnings Preview: What To Expect From Doximity On Tuesday

Doximity's (DOCS) fiscal fourth-quarter results are likely to reflect continued strength in its telehealth platform.

Doximity (DOCS) to Report Q4 Earnings: What's in the Offing?

Axsome Therapeutics

10X Genomics

Here's why three Fool.com contributors love 10x Genomics, Axsome Therapeutics, and Doximity.

My Favorite Biotech

Innovative Industrial Properties

Shopify

Unity Software

If you have a long investing time horizon, these strong performers could deliver massive gains.

4 Stocks That Could Turn $10,000 Into $200,000 by 2040

Doximity has the potential to be a great investment over the long term.

3 Things That Make This an Exciting Growth Stock to Buy Right Now

SAN FRANCISCO , April 26, 2022 /PRNewswire/ -- Doximity, Inc. (NYSE:DOCS), the leading digital platform for U.S. medical professionals, today announced it will report financial results for its fourth quarter ended March 31, 2022 after market close on May 17, 2022. Doximity will host a conference call and webcast at 2:00 p.m.

Doximity to Release Fiscal 2022 Fourth Quarter Results on May 17, 2022

Semrush Holdings

Twilio

These companies strike the right balance of potential and leadership, which could help them achieve strong returns over the next decade.

3 Stocks That Could Turn $200,000 Into $1 Million by 2032

Doximity's revolutionary business model creates a compelling competitive advantage for the company.

1 Unique Business to Buy and Hold for the Next 3 Years

Doximity (DOCS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Will Doximity (DOCS) Beat Estimates Again in Its Next Earnings Report?

Teladoc

Zoom Video

These Ridiculously Cheap Stocks Are Obvious Winners

Is Doximity or Teladoc the better investment right now?

2 Outstanding Healthcare Companies With Huge Potential

By catering to the needs of medical professionals, Doximity could deliver in a big way.

80% of Physicians Use This Platform, and Its Stock Could Benefit

But the company offers much more than a social network for medical professionals.

This Popular Platform Is Dubbed "LinkedIn for Doctors"

Doximity's high valuation hurt the stock even though it didn't publish any bad news in March.

Why Doximity Stock Slumped 15% in March

DocGo

Patient care via phone and video is far from finished.

2 TeleHealth Stocks to Buy, 1 to Watch in 2022

Medtronic

Skylight Health Group

What's a break in the clouds due to the pandemic? Maybe the ease of meeting with your doctor.

3 Best Telemedicine Stocks for Investors

Doximity (DOCS) is a high-quality company which we previously covered. At the time we came to the conclusion shares were too expensive.

Doximity: Turning Bullish After Stock Price Correction

Ortho Clinical Diagnostics Holdings

OCDX vs. DOCS: Which Stock Is the Better Value Option?

Applied Materials

Long-term deals abound after a brutal sell-off that started 2022.

3 Investors Share Their Stock Shopping Lists

If you were one of the early investors in Doximity Inc. ( DOCS , Financial), take a bow. If you got in early on Zymergen Inc. ( ZY , Financial) or Talis Biomedical Corp. ( TLIS , Financial), my sincerest condolences.

Doximity Stock a Top Performer Among 2021 Medtech IPOs

Fiverr

Revolve

This market provides plenty of opportunities for great deals.

3 Unstoppable Stocks You Can Buy Right Now for Less Than $100

Alnylam Pharmaceuticals

Moderna

These former stock market darlings could recoup some of the heavy losses they recently suffered.

3 Healthcare Stocks That Could Rise 28% or More, According to Wall Street

There are some wonderful deals to be had after a bonkers sell-off for all things "growth" stock.

3 Top Growth Stocks That Are a Fantastic Long-Term Value

Datadog

Investors are anticipating a Federal Reserve rate hike this week.

News for Doximity Stock (DOCS)